01
March
2023
|
07:59 AM
Europe/Amsterdam
Not intended for U.S. and UK Media
Summary
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with comparable visual acuity as well as rapid and resilient fluid control to the comparator EyleaTM (aflibercept 2 mg) through to week 48 / Safety of aflibercept 8 mg was consistent with the safety profile of Eylea (aflibercept 2 mg) / Extended treatment intervals with fewer injections addresses an important patient need
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Bayer.com – https://www.bayer.com/media/en-us/bayer-submits-aflibercept-8-mg-for-marketing-authorization-in-japan/
